肿瘤-睾丸抗原MAGE-1和NY-ESO-1 mRNA在胃肠间质瘤中的表达

Clinical implications of expression of MAGE-1 and NY-ESO-1 mRNAs in gastrointestinal stromal tumors

目的:探讨肿瘤-睾丸抗原(CTA)MAGE-1和NY-ESO-1作为胃肠间质瘤(GISTs)免疫治疗特异性靶点及MAGE-1和NY-ESO-1mRNA作为辅助GISTs危险度分级指标的可能性,及其与GISTs生物学行为的关系.方法:采用逆转录-聚合酶链反应(RT-PCR)技术,检测30例GISTs中MAGE-1和NY-ESO-1m R NA的表达,并取正常胃肠道组织作为阴性对照组,同时分析MAGE-1和NY-ESO-1mRNA表达与病理特征的关系.结果:正常对照组中无阳性表达,30例GISTs中,18例至少表达一种CTA,MAGE-1和NY-E S O-1m R NA在G I S T s中的表达率分别为30%和47%.MAGE-1和NY-ESO-1mRNA表达与患者年龄、性别和病理类型无关,而与肿瘤生长部位、肿瘤大小及危险度分级有关(P<0.05).MAGE-1和NY-ESO-1mRNA在低危、中危、高危三个组中表达量随着危险度分级的升高而增高,三组间差异有统计学意义(P<0.05).MAGE-1和NY-ESO-1mRNA在GISTs中的表达不存在相关性(r=0.018,P>0.05).结论:MAGE-1和NY-ESO-1mRNA在GISTs中的高特异性表达,其抗原有望成为GISTs免疫治疗特异性的靶点;MAGE-1和NY-ESO-1mRNA表达与GISTs危险度分级有关,MAGE-1和NY-ESO-1mRNA有望成为辅助GISTs危险度分级的诊断指标.

AIM： To evaluate the possibility of using melanoma antigen-1 （MAGE-1） and New York-esophageal-1 （NY-ESO-1） antigens as specific targets for immunotherapy of gastrointestinal stromal tumors （GISTs） and using MAGE-1 and NY-ESO-1 mRNA levels as auxiliary parameters for risk classification of GISTs. METHODS： The expression of MAGE-1 and NY-ESO-1 mRNAs was detected by reverse transcription-polymerase chain reaction （RT- PCR） in 30 GIST tissue specimens. The cor-relation of MAGE-1 and NY-ESO-1 mRNA expression with pathological parameters was analyzed in GISTs. RESULTS： The positive rates of MAGE-1 and NY-ESO-1 mRNA expression in GIST specimens were 30% and 47%, respectively. At least one of these two cancer-testis antigens （CTAs） was detected in 18 GIST tissue specimens. The expression of MAGE-1 and NY-ESO-1 mRNAs was not correlated with age, sex or pathologic type （P 〉 0.05）, but correlated with tumor site, tumor diameter and risk grade （all P 〈 0.05）. The expression levels of MAGE-1 and NY-ESO-1 mRNAs in GISTs of high risk grade were significantly higher than those in GISTs of low risk grade （P 〈 0.05）. No negative correlation was noted between the expression of MAGE-1 and NY-ESO-1 mRNAs in GISTs （r = 0.018, P 〉 0.05）. CONCLUSION： MAGE-1 and NY-ESO-1 mRNAs are expressed specifically in GIST tissue and may be potentially promising targets for antigen-specific immunotherapy of GISTs. The expression of MAGE-1 and NY-ESO-1 mRNAs is correlated with the risk grade of GISTs. MAGE-1 and NY-ESO-1 mRNA levels are promising auxiliary parameters for risk classification of GISTs.